Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study

One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL) deals with the choice between continuous or fixed-duration therapy. Continuous ibrutinib (IB), the first-in-class BTK inhibitor, and obinutuzumab-chlorambucil (G-CHL) are commonly used therapies for elderly a...

Descripción completa

Detalles Bibliográficos
Autores principales: Visentin, Andrea, Mauro, Francesca Romana, Catania, Gioachino, Fresa, Alberto, Vitale, Candida, Sanna, Alessandro, Mattiello, Veronica, Cibien, Francesca, Sportoletti, Paolo, Gentile, Massimo, Rigolin, Gian Matteo, Quaglia, Francesca Maria, Murru, Roberta, Gozzetti, Alessandro, Molica, Stefano, Marchetti, Monia, Pravato, Stefano, Angotzi, Francesco, Cellini, Alessandro, Scarfò, Lydia, Reda, Gianluigi, Coscia, Marta, Laurenti, Luca, Ghia, Paolo, Foà, Robin, Cuneo, Antonio, Trentin, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719965/
https://www.ncbi.nlm.nih.gov/pubmed/36479077
http://dx.doi.org/10.3389/fonc.2022.1033413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719965/
https://www.ncbi.nlm.nih.gov/pubmed/36479077
http://dx.doi.org/10.3389/fonc.2022.1033413

Ejemplares similares